Saville B A, Gray M R, Tam Y K
Department of Chemical Engineering and Applied Chemistry, University of Toronto, Ontario, Canada.
Drug Metab Rev. 1992;24(1):49-88. doi: 10.3109/03602539208996290.
The liver is, by nature, heterogeneous. It contains a complex vascular network for blood flow and a stationary phase consisting of enzymes within parenchymal cells. Several physiological processes, therefore, may combine to give observed ranges in drug elimination. Net changes in concentration are a consequence of a series of steps: uptake of substrate into liver cells, enzymatic reactions within the cells, release of metabolites and unconverted substrate from the cells into the sinusoids, and the net flow of the perfusing medium in the vasculature. In addition, substrate binding to proteins in the blood and in the liver can influence hepatic elimination. An understanding of each of these processes is necessary to fully comprehend the overall process of drug elimination, and these processes must be accounted for, either individually or by grouping and approximation, if a model for drug elimination is to be developed. Existing models of hepatic elimination may be classified according to their treatment of mixing within the vasculature and whether or not the model explicitly accounts for mass transfer between the heterogeneous phases of the liver. Four major classes may be defined: 1. Nonparametric homogeneous models, which assume that either complete mixing or no mixing occurs within the vasculature of the organ. 2. Homogeneous mixing models, which allow for a range of mixing phenomena. 3. Heterogeneous micromixing models, which allow for mass transport between the cells and vasculature and describe mixing within the vasculature on a microscopic level. 4. Heterogeneous compartmental models, which also describe interphase mass transfer but assume complete mixing on a microscopic level, and therefore use a time and spatially averaged approach to model mixing. The utility of these models of hepatic elimination will be critically assessed based upon (1) their ability to account for the influence of the aforementioned physiological processes upon elimination; (2) the data requirements of the model, in addition to its mathematical complexity and ease of use; and (3) the range of compounds and metabolites which may be described using the model.
肝脏本质上是异质性的。它包含一个用于血流的复杂血管网络以及由实质细胞内的酶组成的固定相。因此,几种生理过程可能共同作用,导致观察到的药物消除范围。浓度的净变化是一系列步骤的结果:底物被摄取到肝细胞中、细胞内的酶促反应、代谢产物和未转化的底物从细胞释放到肝血窦中,以及灌注介质在脉管系统中的净流动。此外,底物与血液和肝脏中的蛋白质结合会影响肝脏消除。要全面理解药物消除的整体过程,必须了解这些过程中的每一个,如果要开发药物消除模型,就必须单独或通过分组和近似来考虑这些过程。现有的肝脏消除模型可以根据它们对脉管系统内混合的处理方式以及模型是否明确考虑肝脏异质相之间的质量传递进行分类。可以定义四大类:1. 非参数均匀模型,其假设在器官的脉管系统内要么完全混合要么不混合。2. 均匀混合模型,其允许一系列混合现象。3. 异质微混合模型,其允许细胞与脉管系统之间的质量传递,并在微观层面描述脉管系统内的混合。4. 异质隔室模型,其也描述相间质量传递,但假设在微观层面完全混合,因此使用时间和空间平均方法来模拟混合。将基于以下几点对这些肝脏消除模型的效用进行严格评估:(1) 它们解释上述生理过程对消除影响的能力;(2) 模型的数据要求,以及其数学复杂性和易用性;(3) 使用该模型可以描述的化合物和代谢产物的范围。